Faculty

Rongfu Wang

Rongfu Wang

Professor of Pediatrics and Medicine
Pediatrics
4650 Sunset Blvd, Mail Stop 57 Off Campus Los Angeles

CHLA, USC: Endowed Chair in Cell Therapy Research, 2019

Houston Methodist/Weill Cornell Medicine: President’s Award for Transformative Excellence, 2016

Houston Methodist/Weill Cornell Medicine: Award for Excellence in Research and Publication, 2016

Houston Methodist/Weill Cornell Medicine: Award for Excellence in Transformative Research, 2016

Houston Methodist/Weill Cornell Medicine: President’s Award for Transformative Excellence, 2013

Baylor College of Medicine: Jack L. Titus Endowed Professorship, 2007

Baylor College of Medicine: DeBakey Excellence in Research Award, 2006

American Cancer Society: American Cancer Society Research Scholar, 2003

National Cancer Institute, NIH: Intramural Research Award, 1999

NIH: Recipient of NIH Fellows Award for Research Excellence, 1996

University of Georgia: Winner of the campus-wide Distinguished Dissertation competition, 1992

BECN2 (beclin 2) Negatively Regulates Inflammasome Sensors Through ATG9A-Dependent but ATG16L1- and LC3-Independent Non-Canonical Autophagy Autophagy. 2022 02; 18(2):340-356. . View in PubMed

Microbiota regulate innate immune signaling and protective immunity against cancerCell Host Microbe. 2021 06 09; 29(6):959-974. e7. . View in PubMed

BECN2 (beclin 2)-mediated non-canonical autophagy in innate immune signaling and tumor development Autophagy. 2020 12; 16(12):2310-2312. . View in PubMed

Evaluation of Single-Cell Cytokine Secretion and Cell-Cell Interactions with a Hierarchical Loading Microwell Chip Cell Rep. 2020 04 28; 31(4):107574. . View in PubMed

RTP4 inhibits IFN-I response and enhances experimental cerebral malaria and neuropathology Proc Natl Acad Sci U S A. 2020 08 11; 117(32):19465-19474. . View in PubMed

Cell-Penetrating Nanoparticles Activate the Inflammasome to Enhance Antibody Production by Targeting Microtubule-Associated Protein 1-Light Chain 3 for Degradation ACS Nano. 2020 03 24; 14(3):3703-3717. . View in PubMed

Beclin 2 negatively regulates innate immune signaling and tumor development J Clin Invest. 2020 10 01; 130(10):5349-5369. . View in PubMed

PHF20 Promotes Glioblastoma Cell Malignancies Through a WISP1/BGN-Dependent Pathway Front Oncol. 2020; 10:573318. . View in PubMed

The E3 ubiquitin ligase MARCH1 regulates antimalaria immunity through interferon signaling and T cell activation Proc Natl Acad Sci U S A. 2020 07 14; 117(28):16567-16578. . View in PubMed

Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis J Neuroinflammation. 2019 Mar 01; 16(1):53. . View in PubMed

Myeloid loss of Beclin 1 promotes PD-L1hi precursor B cell lymphoma development J Clin Invest. 2019 12 02; 129(12):5261-5277. . View in PubMed

Investigation of parameters that determine Nano-DC vaccine transport Biomed Microdevices. 2019 04 04; 21(2):39. . View in PubMed

JMJD3 regulates CD4 T cell trafficking by targeting actin cytoskeleton regulatory gene Pdlim4 J Clin Invest. 2019 08 08; 129(11):4745-4757. . View in PubMed

Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report Oncol Lett. 2018 Dec; 16(6):6998-7007. . View in PubMed

DHX29 functions as an RNA co-sensor for MDA5-mediated EMCV-specific antiviral immunity PLoS Pathog. 2018 02; 14(2):e1006886. . View in PubMed

Inflammasome activation negatively regulates MyD88-IRF7 type I IFN signaling and anti-malaria immunity Nat Commun. 2018 11 23; 9(1):4964. . View in PubMed

PHF20 collaborates with PARP1 to promote stemness and aggressiveness of neuroblastoma cells through activation of SOX2 and OCT4 J Mol Cell Biol. 2018 04 01; 10(2):147-160. . View in PubMed

Tgfbr2 inactivation facilitates cellular plasticity and development of Pten-null prostate cancer J Mol Cell Biol. 2018 08 01; 10(4):316-330. . View in PubMed

Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma Front Immunol. 2018; 9:2924. . View in PubMed

Detection of host pathways universally inhibited after Plasmodium yoelii infection for immune intervention Sci Rep. 2018 10 16; 8(1):15280. . View in PubMed

LRRC25 inhibits type I IFN signaling by targeting ISG15-associated RIG-I for autophagic degradation EMBO J. 2018 02 01; 37(3):351-366. . View in PubMed

BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1 Nat Commun. 2018 02 05; 9(1):500. . View in PubMed

Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma J Control Release. 2018 02 28; 272:72-82. . View in PubMed

Selection of reference genes for gene expression studies in human bladder cancer using SYBR-Green quantitative polymerase chain reaction Oncol Lett. 2017 Nov; 14(5):6001-6011. . View in PubMed

Assembly of the WHIP-TRIM14-PPP6C Mitochondrial Complex Promotes RIG-I-Mediated Antiviral SignalingMol Cell. 2017 Oct 19; 68(2):293-307. e5. . View in PubMed

The distribution and function of human memory T cell subsets in lung cancer Immunol Res. 2017 06; 65(3):639-650. . View in PubMed

CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer Oncogene. 2017 04; 36(15):2095-2104. . View in PubMed

The Characteristics of Naive-like T Cells in Tumor-infiltrating Lymphocytes From Human Lung Cancer J Immunother. 2017 01; 40(1):1-10. . View in PubMed

A special issue on cancer immunotherapy Cell Res. 2017 01; 27(1):1-2. . View in PubMed

Histone demethylases UTX and JMJD3 are required for NKT cell development in mice Cell Biosci. 2017; 7:25. . View in PubMed

USP26 functions as a negative regulator of cellular reprogramming by stabilising PRC1 complex components Nat Commun. 2017 08 24; 8(1):349. . View in PubMed

TRIM45 functions as a tumor suppressor in the brain via its E3 ligase activity by stabilizing p53 through K63-linked ubiquitination Cell Death Dis. 2017 05 25; 8(5):e2831. . View in PubMed

Sci Rep. 2017 10 18; 7(1):13448. . View in PubMed

Immune targets and neoantigens for cancer immunotherapy and precision medicine Cell Res. 2017 Jan; 27(1):11-37. . View in PubMed

FOSL1 Inhibits Type I Interferon Responses to Malaria and Viral Infections by Blocking TBK1 and TRAF3/TRIF Interactions mBio. 2017 01 03; 8(1). . View in PubMed

NLRP11 attenuates Toll-like receptor signalling by targeting TRAF6 for degradation via the ubiquitin ligase RNF19A Nat Commun. 2017 12 07; 8(1):1977. . View in PubMed

Increased CD40 Expression Enhances Early STING-Mediated Type I Interferon Response and Host Survival in a Rodent Malaria Model PLoS Pathog. 2016 Oct; 12(10):e1005930. . View in PubMed

USP19 modulates autophagy and antiviral immune responses by deubiquitinating Beclin-1 EMBO J. 2016 Apr 15; 35(8):866-80. . View in PubMed

TRIM9 short isoform preferentially promotes DNA and RNA virus-induced production of type I interferon by recruiting GSK3ß to TBK1 Cell Res. 2016 05; 26(5):613-28. . View in PubMed

TRIM11 Suppresses AIM2 Inflammasome by Degrading AIM2 via p62-Dependent Selective Autophagy Cell Rep. 2016 08 16; 16(7):1988-2002. . View in PubMed

TRIM14 Inhibits cGAS Degradation Mediated by Selective Autophagy Receptor p62 to Promote Innate Immune Responses Mol Cell. 2016 10 06; 64(1):105-119. . View in PubMed

The BECN1-USP19 axis plays a role in the crosstalk between autophagy and antiviral immune responses Autophagy. 2016 07 02; 12(7):1210-1. . View in PubMed

USP38 Inhibits Type I Interferon Signaling by Editing TBK1 Ubiquitination through NLRP4 Signalosome Mol Cell. 2016 10 20; 64(2):267-281. . View in PubMed

Cross-Regulation of Two Type I Interferon Signaling Pathways in Plasmacytoid Dendritic Cells Controls Anti-malaria Immunity and Host Mortality Immunity. 2016 11 15; 45(5):1093-1107. . View in PubMed

Targeting epigenetic regulations in cancer Acta Biochim Biophys Sin (Shanghai). 2016 Jan; 48(1):97-109. . View in PubMed

J Cell Biol. 2015 Dec 07; 211(5):1025-40. . View in PubMed

JMJD3 as an epigenetic regulator in development and disease Int J Biochem Cell Biol. 2015 Oct; 67:148-57. . View in PubMed

Sci Rep. 2015 Aug 04; 5:12738. . View in PubMed

Genome-wide Analysis of Host-Plasmodium yoelii Interactions Reveals Regulators of the Type I Interferon Response Cell Rep. 2015 Jul 28; 12(4):661-72. . View in PubMed

Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response Cell Rep. 2015 May 12; 11(6):957-966. . View in PubMed

Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells PLoS One. 2015; 10(5):e0124094. . View in PubMed

Critical role of histone demethylase Jmjd3 in the regulation of CD4+ T-cell differentiation Nat Commun. 2014 Dec 22; 5:5780. . View in PubMed

Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma BMC Cancer. 2014 Nov 18; 14:836. . View in PubMed

An epigenetic switch induced by Shh signalling regulates gene activation during development and medulloblastoma growth Nat Commun. 2014 Nov 05; 5:5425. . View in PubMed

The future potential for cocaine vaccines Expert Opin Biol Ther. 2014 Sep; 14(9):1271-83. . View in PubMed

Stage-dependent and locus-specific role of histone demethylase Jumonji D3 (JMJD3) in the embryonic stages of lung development PLoS Genet. 2014 Jul; 10(7):e1004524. . View in PubMed

USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors Cell Res. 2014 Apr; 24(4):400-16. . View in PubMed

HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer Invest New Drugs. 2014 Apr; 32(2):235-242. . View in PubMed

Strain-specific innate immune signaling pathways determine malaria parasitemia dynamics and host mortality Proc Natl Acad Sci U S A. 2014 Jan 28; 111(4):E511-20. . View in PubMed

Applications of nanomaterials as vaccine adjuvants Hum Vaccin Immunother. 2014; 10(9):2761-74. . View in PubMed

Current advances in T-cell-based cancer immunotherapy Immunotherapy. 2014; 6(12):1265-78. . View in PubMed

Mechanisms and pathways of innate immune activation and regulation in health and cancer Hum Vaccin Immunother. 2014; 10(11):3270-85. . View in PubMed

Exp Parasitol. 2013 Jul; 134(3):389-99. . View in PubMed

Cell type-specific function of TAK1 in innate immune signaling Trends Immunol. 2013 Jul; 34(7):307-16. . View in PubMed

Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation Cell Metab. 2013 Mar 05; 17(3):411-22. . View in PubMed

Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination Cell. 2013 Feb 28; 152(5):1037-50. . View in PubMed

Increased expression of pregnancy up-regulated non-ubiquitous calmodulin kinase is associated with poor prognosis in clear cell renal cell carcinoma PLoS One. 2013; 8(4):e59936. . View in PubMed

Identification of special AT-rich sequence binding protein 1 as a novel tumor antigen recognized by CD8+ T cells: implication for cancer immunotherapy PLoS One. 2013; 8(2):e56730. . View in PubMed

Evidence for GAL3ST4 mutation as the potential cause of pectus excavatum Cell Res. 2012 Dec; 22(12):1712-5. . View in PubMed

Molecular cloning of large alternative transcripts based on comparative phylogenetic analysis and exploration of an EST database Anal Biochem. 2012 May 15; 424(2):140-1. . View in PubMed

Cell Res. 2012 May; 22(5):822-35. . View in PubMed

NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4 Nat Immunol. 2012 Mar 04; 13(4):387-95. . View in PubMed

Immunity. 2012 Jan 27; 36(1):43-54. . View in PubMed

Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy PLoS One. 2012; 7(9):e45756. . View in PubMed

Induced pluripotent stem cell-related genes influence biological behavior and 5-fluorouracil sensitivity of colorectal cancer cells J Zhejiang Univ Sci B. 2012 Jan; 13(1):11-9. . View in PubMed

Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling Adv Immunol. 2012; 114:151-76. . View in PubMed

Immunity. 2011 Jun 24; 34(6):843-53. . View in PubMed

NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways Cell. 2010 Apr 30; 141(3):483-96. . View in PubMed

Molecular cloning and characterization of MHC class I- and II-restricted tumor antigens recognized by T cellsCurr Protoc Immunol. 2009 Feb; Chapter 20:Unit 20. 10. . View in PubMed

CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer Hum Immunol. 2008 Nov; 69(11):811-4. . View in PubMed

Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer Proc Natl Acad Sci U S A. 2008 Oct 07; 105(40):15505-10. . View in PubMed

Tumor-associated galectin-3 modulates the function of tumor-reactive T cells Cancer Res. 2008 Sep 01; 68(17):7228-36. . View in PubMed

Toll-like receptors and immune regulation: implications for cancer therapy Oncogene. 2008 Jan 07; 27(2):181-9. . View in PubMed

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer Clin Cancer Res. 2007 Dec 01; 13(23):6947-58. . View in PubMed

Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway Immunity. 2007 Aug; 27(2):334-48. . View in PubMed

Regulatory T cells and cancer Curr Opin Immunol. 2007 Apr; 19(2):217-23. . View in PubMed

Regulatory T cells and innate immune regulation in tumor immunity Springer Semin Immunopathol. 2006 Aug; 28(1):17-23. . View in PubMed

CD4+ T-cell response to mitochondrial cytochrome B in human melanoma Cancer Res. 2006 Jun 01; 66(11):5919-26. . View in PubMed

Regulatory T cells and toll-like receptors in cancer therapy Cancer Res. 2006 May 15; 66(10):4987-90. . View in PubMed

Regulatory T cells and Toll-like receptors in tumor immunity Semin Immunol. 2006 Apr; 18(2):136-42. . View in PubMed

Functional control of regulatory T cells and cancer immunotherapy Semin Cancer Biol. 2006 Apr; 16(2):106-14. . View in PubMed

Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer Semin Cancer Biol. 2006 Feb; 16(1):73-9. . View in PubMed

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function Science. 2005 Aug 26; 309(5739):1380-4. . View in PubMed

Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy Microbes Infect. 2005 Jun; 7(7-8):1056-62. . View in PubMed

Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells J Immunol. 2005 Mar 01; 174(5):2661-70. . View in PubMed

Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation Cancer Res. 2005 Feb 15; 65(4):1577-86. . View in PubMed

Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo J Clin Invest. 2004 Aug; 114(4):542-50. . View in PubMed

Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes J Exp Med. 2004 Feb 16; 199(4):459-70. . View in PubMed

Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy Immunity. 2004 Jan; 20(1):107-18. . View in PubMed

Identification of MHC class II-restricted tumor antigens recognized by CD4+ T cells Methods. 2003 Mar; 29(3):227-35. . View in PubMed

Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells Cancer Res. 2002 Dec 15; 62(24):7195-9. . View in PubMed

Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme Cancer Res. 2002 Oct 01; 62(19):5505-9. . View in PubMed

Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens Immunol Rev. 2002 Oct; 188:65-80. . View in PubMed

Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion Clin Immunol. 2002 Jul; 104(1):14-20. . View in PubMed

T cell-mediated immune responses in melanoma: implications for immunotherapy Crit Rev Oncol Hematol. 2002 Jul; 43(1):1-11. . View in PubMed

Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design Cancer Res. 2002 Jul 01; 62(13):3630-5. . View in PubMed

Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis J Exp Med. 2002 Jun 03; 195(11):1397-406. . View in PubMed

Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells J Clin Invest. 2002 Jun; 109(11):1463-70. . View in PubMed

Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells Nat Biotechnol. 2002 Feb; 20(2):149-54. . View in PubMed

Immunization against endogenous retroviral tumor-associated antigens Cancer Res. 2001 Nov 01; 61(21):7920-4. . View in PubMed

The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity Trends Immunol. 2001 May; 22(5):269-76. . View in PubMed

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production Proc Natl Acad Sci U S A. 2001 Mar 27; 98(7):3964-9. . View in PubMed

MHC class II-restricted tumor antigens and CD4+ T cells play a role in hematological malignancies as well as solid tumors Trends in Immunology. 2001; 22(8):423. . View in PubMed

Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules J Immunol. 2000 Jul 15; 165(2):1153-9. . View in PubMed

Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma J Immunother. 2000 Jan; 23(1):17-27. . View in PubMed

Human tumor antigens: implications for cancer vaccine development J Mol Med (Berl). 1999 Sep; 77(9):640-55. . View in PubMed

Human tumor antigens for cancer vaccine development Immunol Rev. 1999 Aug; 170:85-100. . View in PubMed

Cancer therapy using a self-replicating RNA vaccine Nat Med. 1999 Jul; 5(7):823-7. . View in PubMed

Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen Science. 1999 May 21; 284(5418):1351-4. . View in PubMed

Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells J Exp Med. 1999 May 17; 189(10):1659-68. . View in PubMed

NY-ESO-1 may be a potential target for lung cancer immunotherapy Cancer J Sci Am. 1999 Jan-Feb; 5(1):20-5. . View in PubMed

A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames J Immunol. 1998 Oct 01; 161(7):3598-606. . View in PubMed

Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens Cancer Res. 1998 Aug 15; 58(16):3519-25. . View in PubMed

The use of melanosomal proteins in the immunotherapy of melanoma J Immunother. 1998 Jul; 21(4):237-46. . View in PubMed

Escherichia coli mrsC is an allele of hflB, encoding a membrane-associated ATPase and protease that is required for mRNA decay J Bacteriol. 1998 Apr; 180(7):1929-38. . View in PubMed

The Escherichia coli mrsC gene is required for cell growth and mRNA decay J Bacteriol. 1998 Apr; 180(7):1920-8. . View in PubMed

Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33 J Immunol. 1998 Jan 15; 160(2):890-7. . View in PubMed

Tumor antigens discovery: perspectives for cancer therapy Mol Med. 1997 Nov; 3(11):716-31. . View in PubMed

Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins Cancer Res. 1997 Jan 15; 57(2):202-5. . View in PubMed

Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes J Exp Med. 1996 Dec 01; 184(6):2207-16. . View in PubMed

Human tumor antigens recognized by T lymphocytes: implications for cancer therapy J Leukoc Biol. 1996 Sep; 60(3):296-309. . View in PubMed

Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen J Exp Med. 1996 Mar 01; 183(3):1131-40. . View in PubMed

Identification of the genes encoding cancer antigens: implications for cancer immunotherapy Adv Cancer Res. 1996; 70:145-77. . View in PubMed

Identification of tumor-regression antigens in melanoma Important Adv Oncol. 1996; 3-21. . View in PubMed

Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes J Immunol. 1995 Aug 01; 155(3):1343-8. . View in PubMed

Mammalian cell/vaccinia virus expression vectors with increased stability of retroviral sequences in Escherichia coli: production of feline immunodeficiency virus envelope protein Gene. 1995 Feb 14; 153(2):197-202. . View in PubMed

Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes J Exp Med. 1995 Feb 01; 181(2):799-804. . View in PubMed

Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in Escherichia coli Gene. 1991 Apr; 100:195-9. . View in PubMed

Dr. Rongfu Wang is a Professor of Pediatrics for the Cancer and Blood Disease Institute and the Division of Hematology, Oncology and Transplantation & Cellular Therapy at Children’s Hospital Los Angeles (CHLA), is an Endowed Chair and Director of the Cell Therapy Research Program at CHLA. He is also a Professor of Medicine, the Keck School of Medicine at the University of Southern California.

Dr. Wang received his Ph.D. degree in Molecular Genetics at the University of Georgia in 1992, and completed his postdoctoral training with the Department of Microbiology and Immunology at Stanford University School of Medicine in 1994. He then completed a Cancer Immunotherapy Fellowship with Dr. Steve Rosenberg at the National Cancer Institute in 1996 and continued as a Senior Investigator until 2000 at the National Cancer Institute, NIH. During his tenure at NCI, Dr. Wang made seminal contributions to cancer antigen discovery and cancer immunotherapy.

In 2000, Dr. Wang was appointed as an Associate Professor in the Department of Immunology at Baylor College of Medicine. At Baylor, he continued his work in identifying new cancer antigens and developing cancer vaccines. In 2004, Dr. Wang was promoted to Professor with tenure. In 2006, he received the Michael DeBakey Excellence in Research Award and in 2007 he was granted the endowed Jack L. Titus Professorship. In 2011, Dr. Wang moved his laboratory to Houston Methodist Research Institute, where he built and became Director of a new Center for Inflammation and Epigenetics with an appointment as Professor in the Department of Microbiology and Immunology at Weill Cornell Medicine, Cornell University. Because of his outstanding contribution, Dr. Wang received several awards, including Presidential Awards in 2013 and 2016 in Houston Methodist Research Institute. Since 2019, Dr. Wang and his team joined University of Southern California.

Research interests of Dr. Wang include cancer antigen discovery, cancer immunotherapy, innate immune signaling, and epigenetic reprogramming of stem cells and immune cells. Throughout his career, Dr. Wang has discovered numerous cancer antigens, some (NY-ESO-1) of which have been demonstrated in clinical studies with TCR-T cell immunotherapy. His team has identified antigen-specific regulatory T cells, which can be reversed by Toll-Like Receptor 8 signaling, and discovered critical epigenetic regulators in T-cell differentiation and in induced pluripotent stem cell reprogramming. Dr. Wang’s research findings have been published in the top journals, including Science, Cell, Immunity, Nature Immunology, Nature Medicine, Nature Biotechnology, Cell Metabolism, Cell host & Microbe, JEM, JCI and Mol. Cell. More recently, his team developed novel self-assembled peptide nanoparticles (SAPNANO) technology, novel CAR-T technology and neoantigen discovery platform for vaccine and CAR/TCR-T immunotherapy. To further understand and improve the T cell trafficking and persistence, Dr. Wang and his team reprogram immune cells and tumor microenvironment by using epigenetic, metabolic and microbiota approaches, thus leading to the development of novel and robust cancer therapeutics. In addition, Dr. Wang investigates microbiota and innate immune signaling to modulate immunity against cancer, infectious disease and Alzheimer’s disease.
sc ctsi logoPowered by SC CTSI

Affiliated Faculty at UPC